Overview
BI
BACE Inhibitor
Progress Confidential
- VTP-27999, Vitae Pharmaceuticals' wholly-owned renin inhibitor has completed Phase 1 studies and is designed to improve the treatment of patients with Chronic Kidney Disease (CKD).
- Renin is the first and rate-limiting step in the renin-angiotensin-system (RAS) pathway. RAS components are located in critical organs throughout the body (kidney, heart, brain) and RAS activity has direct effects on tissues, playing a key role in kidney damage.
- Vitae Pharmaceuticals' second program, partnered with Boehringer Ingelheim, focuses on inhibition of 11ß-hydroxysteroid dehydrogenase (HSD)-1 for the treatment of diabetes and associated metabolic diseases is currently in Phase 1 clinical trials.
- 11ß-HSD-1 is a recently validated, new diabetes target, which has demonstrated broad, potential metabolic syndrome benefit.
- Vitae Pharmaceuticals' beta-secretase (BACE) program, also partnered with Boehringer Ingelheim, has identified potent and bioavailable inhibitors that have demonstrated the ability to cross the blood-brain barrier and lower brain amyloid-beta (Aß or Abeta) peptide following a single oral dose in preclinical, in vivo models of Alzheimer's disease.
- Inhibition of BACE, an enzyme involved in the formation of amyloid-beta plaques that accumulate in the brains of patients with Alzheimer's disease, is a leading prospect for slowing or even halting disease progression.
- Vitae Pharmaceuticals has initiated a program to treat atherosclerosis by modulating LXR, an approach that increases reverse cholesterol transport (RCT), decreases inflammation and is complementary to the LDL-lowering capabilities of statins.
- In 12 months, Vitae scientists have discovered novel, small molecule compounds that induce the expression of RCT biomarkers without the induction of triglycerides in rodent and primate models.
